E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-small cell lung cancer (NSCLC) |
|
E.1.1.1 | Medical condition in easily understood language |
NSCLC is the most common type of lung cancer that originally arises from the lungs and could spread to areas near the lungs or distantly to other organs. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029518 |
E.1.2 | Term | Non-small cell lung cancer stage II |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029519 |
E.1.2 | Term | Non-small cell lung cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of RO7198457 plus atezolizumab compared with atezolizumab. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the safety and tolerability of RO7198457 plus atezolizumab compared with atezolizumab alone • To characterize the pharmacokinetics of RO7198457 and atezolizumab when administered concurrently • To evaluate the immune response to atezolizumab when administered concurrently with RO7198457. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age >= 18 years - Resected Stage II-III NSCLC per American Joint Committee on Cancer staging criteria, 8th revised edition - Complete R0 resection of Stage II or III NSCLC prior to enrollment and adequate recovery from surgery - Pathological evaluation of mediastinal lymph nodes preoperatively or intraoperatively - ctDNA (circulating tumor DNA) identified in plasma after resection of Stage II-III NSCLC and prior to start of adjuvant platinum-doublet therapy, as determined by central testing - Treatment with at least two cycles of adjuvant platinum-doublet chemotherapy regimens for resected NSCLC - No unequivocal evidence of disease after surgery and adjuvant platinum-doublet chemotherapy, as assessed on imaging computed tomography or magnetic resonance scans) within 28 days prior to randomization - Availability of adequate tumor material - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 - Adequate hematologic and end-organ function - Negative HIV test at screening - Negative hepatitis B test at screening - Negative hepatitis C test at screening. |
|
E.4 | Principal exclusion criteria |
- Patients with a known mutation in exons 18-21 of EGFR or with a known ALK or ROS alteration - History of malignancy other than disease under study within 5 years prior to enrollment, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer - Induction and neoadjuvant systemic therapy prior to resection of NSCLC - Radiotherapy prior to or after resection of NSCLC - Prior systemic investigational therapy - Prior anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or a cancer vaccine - Treatment with systemic immunostimulatory agents within 6 weeks or 5 drug elimination half-lives, prior to initiation of study treatment - Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment - Treatment with monoamine oxidase inhibitors (MAOIs) within 3 weeks prior to initiation of study treatment or requirement for ongoing treatment with MAOIs - Active or history of autoimmune disease or immune deficiency - Known primary immunodeficiencies, either cellular or combined T-cell and B-cell immunodeficiencies - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan - Significant cardiovascular disease - Major surgical procedure, other than for diagnosis or for resection of disease under current study, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study - Known active or latent tuberculosis infection - Recent acute infection - Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment - Prior allogeneic stem cell or solid organ transplantation - Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications - Known clinically significant liver disease - Previous splenectomy - History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins - Known hypersensitivity to Chinese hamster ovary cell products or any component of the atezolizumab formulation - Known allergy or hypersensitivity to any component of RO7198457 - Pregnant or lactating women. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 2. Change from baseline in targeted vital signs 3. Change from baseline in targeted clinical laboratory test results 4. Plasma concentrations of RNA at specified timepoints 5. Plasma concentrations of DOTMA [(R)-N,N,N-trimethyl-2,3-dioleyloxy-1-propanaminium chloride] at specified timepoints 6. Maximum serum concentration (Cmax)and minimum serum concentration (Cmin) of atezolizumab at specified timepoints 7. Prevalence of anti-drug antibodies (ADAs) to atezolizumab at baseline and incidence of ADAs to atezolizumab during the study. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Up to 90 days after the final dose of study drug or until initiation of another systemic anti-cancer therapy 2-3. Baseline (Day-28 to -1) to 90 days after the final dose of study drug 4-5. Arm B: Day 1, 8, 15, 22 of Cycle 1, Day 1 of Cycle 2, 3, 5, 7, 9, 11 and treatment discontinuation (TD) visit 6. Arm A and Arm B: Day 1 of Cycle 1-4 and at TD 7. Arm A and Arm B: Baseline, Day 1 of Cycle 1-4 and at TD. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
evaluate the immune response to atezolizumab when administered concurrently with RO7198457 and tolerability of RO7198457 plus atezolizumab compared with atezolizumab alone.
|
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Japan |
Korea, Republic of |
United States |
France |
Germany |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of this study is defined as the date when the last data required for all study analysis have been collected. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 48 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 62 |